Averoa

What Averoa does

Averoa is a privately held French biopharmaceutical company incorporated as AVEROA SAS, founded in December 2021 in Meylan (Grenoble), France, to develop and commercialize therapies for unmet needs in nephrology. The company's lead product, XOANACYL® (AVA1014, Ferric Citrate Coordination Complex), is an oral therapy approved by the European Commission in June 2025 and by the UK MHRA in October 2025 for the concomitant treatment of iron deficiency anaemia and hyperphosphatemia in adult chronic kidney disease (CKD) patients. The asset was in-licensed from Akebia Therapeutics in December 2022 (where it is already marketed as Auryxia in the US and Riona in Japan) and Averoa holds exclusive development and commercialization rights for Europe, UK, Switzerland, and Turkey.

The portfolio is being expanded through the LUCIOL project, a research collaboration with IDIBELL, CIBER, and the University of Barcelona focused on renal lithiasis and cystinuria. The pipeline comprises AVA2206, a natural thiolhistidine antioxidant in late preclinical development for cystinuria, which has received Orphan Drug Designation from both the EMA and US FDA, and AVA2065, a companion diagnostic biomarker validated in preclinical models. Intellectual property includes registered trademarks (XOANACYL®, AVEROA) and formulation patents held by senior staff (four patents, three granted in EU, US, and Japan, held by the COO; two additional formulation patents by the Pharmaceutical Development Manager).

The business model combines in-licensing of late-stage assets with strong therapeutic and commercial fit, internal development leveraging regulatory expertise (including repositioning in new indications and pursuing orphan designation), and a planned network of commercial partners and distributors across licensed territories. The go-to-market targets European, UK, Swiss, and Turkish markets for XOANACYL®, with revenue mechanics based on product sales through this partner network. Averoa operates with a lean team of 1-10 employees and is led by an experienced management group including Dr. Luc-André Granier (President & CEO; co-founder of Advicenne and Panntherapi and the lead on the duloxetine/Cymbalta FDA approval in 2004), Sarah Delbaere (CFO; supported Advicenne's IPO on Euronext), Caroline Roussel-Maupetit (COO), Scott Donald (Business Development Director), and senior regulatory and clinical advisors. Share capital is stated at €1,329,799; no institutional funding rounds, revenue figures, or ownership structure beyond founder control are publicly disclosed.

Name

Averoa

Legal name

AVEROA SAS

Website

https://averoa-pharma.org

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Averoa is a private French biopharmaceutical company developing therapies for renal diseases, including XOANACYL® (approved in the EU and UK for iron deficiency anaemia and hyperphosphatemia in CKD) and a pipeline of orphan-designated candidates for cystinuria and renal lithiasis.

Ownership category

akta.pro rank

Product category

Renal Therapeutics / Nephrology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

akta.pro secondary industry

Rare Renal & Nephrology Disorder Therapies (HLAIAIAI)

Keywords

• Renal disease therapeutics
• Chronic kidney disease
• Biopharmaceutical products
• Renal lithiasis treatment
• Prescription pharmaceuticals

Headquarters

HQ city

Meylan

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Product Sales - XOANACYL: Sales of FDA/EMA approved oral therapy XOANACYL (Ferric Citrate) for chronic kidney disease patients with iron deficiency and hyperphosphatemia. Licensed from Akebia Therapeutics and already marketed in US (Auryxia) and Japan (Riona).
2. Licensing and Commercialization Rights: Averoa develops and commercializes in-licensed products in Europe, UK, Switzerland, and Turkey. The company builds portfolio through in-licensing late-stage drugs and develops network of commercial partners and distributors.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Averoa is a biopharmaceutical company that develops and commercializes prescription therapeutics for renal diseases. Its lead product XOANACYL (Ferric Citrate Coordination Complex) is an oral therapy approved in the EU and UK for treating iron deficiency anemia and hyperphosphatemia in adult chronic kidney disease (CKD) patients. The pipeline includes AVA2206 (Orphan Drug Designation from EMA and FDA) and AVA2065 (companion diagnostic biomarker) for renal lithiasis and cystinuria under the LUCIOL project.

Product overview

Averoa is a biopharmaceutical company dedicated to developing innovative medicines for nephrology. Their portfolio consists of XOANACYL® (AVA1014), an approved oral therapy for iron deficiency anemia and hyperphosphatemia in CKD patients, and the LUCIOL project pipeline featuring AVA2206 (a novel antioxidant treatment for renal lithiasis in late preclinical stage with Orphan Drug Designation) paired with AVA2065 (a companion biomarker diagnostic for cystinuria). The approved product and pipeline candidates address distinct therapeutic areas within renal diseases.

Differentiator

Problem solved

Functional benefit

Brands

• XOANACYL® (AVA1014): Ferric Citrate Coordination Complex - oral therapy for treating iron deficiency and elevated serum phosphorus in CKD patients. Received European Marketing Authorisation on June 11, 2025 and UK MHRA Marketing Authorisation on October 30, 2025.
• AVA2206 (LUCIOL project)
• AVA2065

Products and services

• XOANACYL (AVA1014) XOANACYL (Ferric Citrate Coordination Complex) is an oral therapy for treating iron deficiency anemia and elevated serum phosphorus (hyperphosphatemia) in adult patients with Chronic Kidney Disease (CKD). It is the only treatment approved in Europe and the UK for these concomitant complications in adult CKD patients.
• AVA2206 AVA2206 is a natural thiolhistidine antioxidant in late preclinical development for treating renal lithiasis, specifically cystinuria. It targets the early process of crystallization to prevent stone formation and has received Orphan Drug Designation from both the EMA and US FDA.
• AVA2065 AVA2065 is a preclinical cystine lithiasis biomarker designed as a companion diagnostic test to predict stone formation and assess treatment response in cystinuria patients.

Quantifiable outcome

• 50% recurrence rate at 5 years without intervention for renal lithiasis
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and secondary.

• Akebia Therapeutics, Inc. (AKBA)coreOEM/ Whitelabel/ Licensing Partner · 1 December 2022Exclusive Licence agreement granting AVEROA rights to develop and commercialize AVA1014 (XOANACYL) in Europe, UK, Switzerland and Turkey. The product was licensed in December 2022. AVA1014 is already registered and marketed in the US under the brand name Auryxia and in Japan under Riona. Averoa revised the clinical package and regulatory strategy for European market needs, supported by 3 pivotal clinical studies performed by Keryx Biopharmaceuticals (a wholly owned subsidiary of Akebia).
• IDIBELL (Institut d'Investigació Biomèdica de Bellvitge)coreStrategic or Co-development PartnerResearch collaboration and license agreement for development of a biomarker (AVA2065) and new treatment (AVA2206) for renal lithiasis. Collaboration also involves CIBER and University of Barcelona for development and exploitation in the field of kidney and/or metabolic diseases.
• CIBER (Biomedical Research Networking Centres)secondaryStrategic or Co-development PartnerCollaboration partner alongside IDIBELL and University of Barcelona for the LUCIOL project developing AVA2206 and AVA2065 for renal lithiasis treatment and diagnosis.
• University of BarcelonasecondaryStrategic or Co-development PartnerAcademic research partner in the LUCIOL project for development of AVA2206 treatment and AVA2065 biomarker for renal lithiasis in collaboration with IDIBELL and CIBER.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Ardelyx: Ardelyx commercializes tenapanor (Xphozah) for hyperphosphatemia in CKD patients on dialysis in the US. It is a focused emerging player in the same hyperphosphatemia indication that XOANACYL addresses, providing a benchmark for nephrology-focused commercial execution.
• Chinook Therapeutics (acquired by Novartis): Chinook Therapeutics was a clinical-stage nephrology company developing treatments for rare kidney diseases (atrasentan, zigakibart) before its acquisition by Novartis in 2023. It represents a strategic exit benchmark for focused rare renal disease biotechs similar to Averoa's pipeline ambitions.
• Travere Therapeutics: Travere Therapeutics is a rare disease-focused biopharmaceutical company with sparsentan (FILSPARI) approved for IgA nephropathy, a rare kidney disease. It is an emerging player in rare renal therapeutics with comparable orphan-drug commercialization strategies.

Broad incumbents

• Galapagos NV: Belgian-Dutch biopharmaceutical company with historical focus on inflammation and fibrotic diseases including renal indications. While broader in scope, it provides a relevant European mid-cap benchmark for specialty pharma commercial strategy and capital markets positioning.
• Pharming Group: Dutch specialty pharma company commercializing treatments for rare diseases including renal and immunological conditions. It is a relevant European listed comparable for a small-cap specialty pharma scaling through European commercial infrastructure.
• Vifor Pharma (CSL Vifor): Vifor Pharma is a global leader in iron deficiency and nephrology, with products such as Ferinject/Injectafer (IV iron) and a broad renal portfolio. It is a broad incumbent in Averoa's therapeutic categories and represents the dominant established competitor in CKD iron deficiency management across Europe.

Direct peers

• Shield Therapeutics: Shield Therapeutics developed ferric maltol (Accrufer/Feraccru), an oral iron therapy targeting iron deficiency. It shares Averoa's oral iron deficiency therapeutic angle and European commercialization focus, making it a directly comparable specialty pharma peer in adjacent nephrology/iron markets.
• Advicenne: French specialty pharma company founded by Averoa CEO Dr Luc-André Granier, focused on rare renal diseases and nephrology therapeutics including treatments for distal renal tubular acidosis. It is a direct peer sharing founder DNA, therapeutic focus on nephrology, and European commercialization orientation.
• Akebia Therapeutics: Akebia developed and markets ferric citrate (Auryxia) in the US for CKD patients with iron deficiency anemia and hyperphosphatemia. It is Averoa's licensor and the originator of XOANACYL, making it the most directly comparable peer with an overlapping product in the same indication.

Others

• Dicerna Pharmaceuticals (acquired by Novo Nordisk): While focused on RNAi therapeutics rather than nephrology, Dicerna was acquired by Novo Nordisk in 2021 and represents a strategic acquirer profile that has historically targeted renal and rare disease biotech assets, making it relevant for understanding potential exit pathways for Averoa.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/averoa-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Averoa